title: Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.
abstract: There is evidence that the kappa opioid system plays an important role in cocaine addiction and that chronic cocaine administration and withdrawal from chronic cocaine alter kappa opioid receptor (KOPr) density. The present study employed in situ [(35)S]guanosine 5'-O-[gamma-thio]triphosphate acid (GTPgammaS) binding autoradiography to measure KOPr-stimulated activation of G-protein in the caudate putamen, nucleus accumbens core and shell, lateral hypothalamus, basolateral amygdala, substantia nigra compacta, substantia nigra reticulata and ventral tegmental area (VTA), in response to chronic cocaine administration or acute and chronic withdrawal from chronic cocaine. Male Fischer rats were injected i.p. with saline or cocaine three times daily at 1 h intervals in an escalating-dose paradigm for 14 days (from 3x15 mg/kg/injection on days 1-3 up to 3x30 mg/kg/injection on days 10-14). Identically treated separate groups were withdrawn from cocaine or saline for 24 h or 14 days. No significant change in KOPr agonist U-69593-stimulated [(35)S]GTPgammaS was found in the seven regions studied 30 min or 14 days after chronic 14 days escalating-dose binge cocaine administration. However there was an increase in KOPr -stimulated [(35)S]GTPgammaS binding in the VTA (P<0.01) of rats withdrawn for 24 h from chronic cocaine. Our results show a cocaine withdrawal induced increase of KOPr signaling in the VTA, and suggest that the KOPr may play a role in acute withdrawal from cocaine.
authors.affiliation: The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, Box 171, New York, NY 10065, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Piras
authors.forename: Y
authors.initials: Y
authors.lastname: Zhou
authors.forename: S D
authors.initials: SD
authors.lastname: Schlussman
authors.forename: A
authors.initials: A
authors.lastname: Ho
authors.forename: M J
authors.initials: MJ
authors.lastname: Kreek
mesh_terms: D000818:Animals; D001345:Autoradiography; D044482:Benzeneacetamides / Q000494:pharmacology; D003042:Cocaine / Q000008:administration & dosage / Q000009:adverse effects*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism*; D008297:Male; D011759:Pyrrolidines / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D011916:Rats, Inbred F344; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000502:physiology*; D013375:Substance Withdrawal Syndrome / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism; D017557:Ventral Tegmental Area / Q000378:metabolism*
chemical_list: D044482:Benzeneacetamides; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D003042:Cocaine; C045444:U 69593
references.citation: Psychopharmacology (Berl). 2007 Oct;194(3):361-9
references.pmid: 17604981
references.citation: Brain Res. 2003 Jun 6;974(1-2):249-53
references.pmid: 12742644
references.citation: Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
references.pmid: 2899326
references.citation: J Comp Neurol. 1994 Dec 15;350(3):412-38
references.pmid: 7884049
references.citation: Synapse. 2002 Sep 15;45(4):220-9
references.pmid: 12125043
references.citation: Neuroreport. 1993 May;4(5):543-6
references.pmid: 8099817
references.citation: Nat Neurosci. 2005 Nov;8(11):1481-9
references.pmid: 16251991
references.citation: Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):258-62
references.pmid: 15950784
references.citation: Pharmacol Ther. 2007 Nov;116(2):306-21
references.pmid: 17868902
references.citation: Neuroscience. 1999;91(3):971-7
references.pmid: 10391475
references.citation: Neuroreport. 1994 Aug 15;5(13):1613-6
references.pmid: 7819531
references.citation: Psychopharmacology (Berl). 1989;98(2):203-6
references.pmid: 2569217
references.citation: Synapse. 2000 Sep 15;37(4):292-7
references.pmid: 10891866
references.citation: J Pharmacol Exp Ther. 1996 Apr;277(1):359-65
references.pmid: 8613942
references.citation: Brain Res Mol Brain Res. 1993 Sep;19(4):323-7
references.pmid: 7694032
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2938-42
references.pmid: 16477003
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
references.pmid: 1347943
references.citation: J Comp Neurol. 1992 Feb 15;316(3):314-47
references.pmid: 1577988
references.citation: Synapse. 2003 Jan;47(1):26-32
references.pmid: 12422370
references.citation: J Pharmacol Exp Ther. 1993 Sep;266(3):1236-46
references.pmid: 7690399
references.citation: Jpn J Pharmacol. 1992 Apr;58(4):435-42
references.pmid: 1328733
references.citation: Brain Res Bull. 2000 Jul 1;52(4):297-302
references.pmid: 10856828
references.citation: Psychopharmacology (Berl). 2009 Sep;205(4):565-75
references.pmid: 19484223
references.citation: Rev Neurol (Paris). 1990;146(10):570-4
references.pmid: 2263819
references.citation: Psychopharmacology (Berl). 2002 Apr;161(1):17-22
references.pmid: 11967626
references.citation: J Pharmacol Exp Ther. 1999 May;289(2):607-24
references.pmid: 10215631
references.citation: Neurosci Biobehav Rev. 2006;30(2):126-47
references.pmid: 16183121
references.citation: Brain Res. 1991 Mar 15;543(2):227-35
references.pmid: 1905576
references.citation: Eur J Neurosci. 2003 May;17(10):2212-8
references.pmid: 12786988
references.citation: Nat Rev Drug Discov. 2002 Sep;1(9):710-26
references.pmid: 12209151
references.citation: Synapse. 2007 Oct;61(10):820-6
references.pmid: 17621646
references.citation: Eur J Neurosci. 2008 Aug;28(4):759-70
references.pmid: 18671743
references.citation: Pharmacol Biochem Behav. 1996 Jan;53(1):5-9
references.pmid: 8848459
references.citation: Neuroscience. 2000;101(3):619-27
references.pmid: 11113311
references.citation: Neuroscience. 1998 Aug;85(4):1051-9
references.pmid: 9681945
references.citation: Psychopharmacology (Berl). 2004 Apr;173(1-2):146-52
references.pmid: 14712342
references.citation: J Neurosci. 1999 May 15;19(10):4102-9
references.pmid: 10234038
references.citation: Brain Res Bull. 2005 Oct 15;67(3):169-75
references.pmid: 16144651
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7242-6
references.pmid: 7638174
references.citation: Neuroscience. 2008 Jun 2;153(4):1225-34
references.pmid: 18436386
references.citation: Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):13-22
references.pmid: 9716927
references.citation: J Pharmacol Exp Ther. 1994 Feb;268(2):916-21
references.pmid: 8114005
references.citation: Life Sci. 1991;48(21):1991-2003
references.pmid: 1851914
references.citation: J Neurochem. 1990 Sep;55(3):1079-82
references.pmid: 2117048
references.citation: Synapse. 1993 Apr;13(4):357-69
references.pmid: 7683144
references.citation: J Pharmacol Exp Ther. 1993 Jan;264(1):489-95
references.pmid: 8093731
references.citation: Am J Psychiatry. 2005 Aug;162(8):1403-13
references.pmid: 16055761
references.citation: Eur J Pharmacol. 2005 Oct 31;523(1-3):67-70
references.pmid: 16226245
references.citation: J Neural Transm Gen Sect. 1993;91(1):53-66
references.pmid: 8383985